on Systasy Bioscience GmbH
Systasy Bioscience Announces Collaboration Agreement with Ono Pharmaceutical
Systasy Bioscience GmbH, a leading provider of innovative solutions for drug discovery, has announced a collaboration with Ono Pharmaceutical Co., Ltd. This partnership aims to identify new therapeutic targets for neurological disorders.
Using its DNA barcoding technologies, Systasy will work with Ono to uncover new drug targets. Ono will receive worldwide exclusive rights to develop and commercialize pharmaceutical products derived from these findings. Systasy will earn research fees and success-based milestone payments from Ono.
"This partnership highlights our capabilities in uncovering signaling networks," said Dr. Sven Wichert, CEO of Systasy. "We aim to find new treatment options for patients and address unmet medical needs in complex mental disorders."
R. P.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Systasy Bioscience GmbH news